Merit Medical Systems' Squirt cleared in the US:
This article was originally published in Clinica
The Squirt drug-delivery system, developed by Merit Medical Systems, has been cleared by the FDA. The hand-held device is used in conjunction with the company's Fountain infusion device and catheter to deliver treatment for peripheral arterial occlusions, haemodialysis graft occlusions and deep vein thrombosis. It is attached externally to one end of the catheter so that doctors can deliver repeated doses of thrombolytic agents to the patient with one hand. The South Jordan, Utah-based company expects to begin marketing immediately.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.